Patent · US Active

N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides

US11858924B2 · kind B2 · utility

0Cited by

12References

13Claims

0Family size

Assignee

AstraZeneca

Inventors

Jonas BRÅNALT · Gothenburg, SE
Maria JOHANSSON · Gothenburg, SE
Anneli NORDQVIST · Gothenburg, SE
Marianne Swanson · Gothenburg, SE

Key dates

Filing date	Jun 12, 2023
Grant date	Jan 2, 2024
Priority date	—
Expiry date	Jun 12, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D498/10
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5 and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.